An Investigator-Initiated Open-Label, Multiple-Dose Clinical Study to Evaluate the Safety,Tolerability, and Efficacy of Gene Therapy for 2Leber's Congenital Amaurosis With RPE65 Mutation (LCA2)

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1 site in 1 country9 target enrollmentJanuary 10, 2023

ConditionsLeber Congenital Amaurosis

Overview

Phase: Early Phase 1
Intervention: Not specified
Conditions: Leber Congenital Amaurosis
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment: 9
Locations: 1
Primary Endpoint: Incidence and severity of ocular and systemic adverse events
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials Related News

Overview

Brief Summary

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.

Registry

clinicaltrials.gov

Start Date

January 10, 2023

End Date

December 30, 2024

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Responsible Party

Principal Investigator

Peiquan Zhao

Professor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Eligibility Criteria

Inclusion Criteria

•Male or females between 8 and 50 years of age at the time of signing theinformed consent form.
•Willing to adhere to protocol as evidenced by written informed consent orparental permission and subject assent.
•Clinical confirmed diagnosis of Leber congenital amaurosis (LCA) andmolecular diagnosis of LCA due to RPE65 mutations.
•Ability to perform tests of visual and retinal function.
•Visual acuity of ≤ 20/160 or visual field less than 20 degrees in the eye to beinjected.
•Acceptable hematology, clinical chemistry, and urine laboratory parameters.

Exclusion Criteria

•OCT examination determined that the outer nuclear layer was not visible inthe planned injection area (Bleb) in the study eye.
•Presence of epiretinal membrane by OCT.
•Complicating systemic diseases or clinically significant abnormal baselinelaboratory values.
•Complicating systemic diseases would include those in which the diseaseitself, or the treatment for the disease, can alter ocular function.
•Prior ocular surgery within six months.
•Prior gene therapy or oligonucleotide therapy treatments.
•Any other condition that would not allow the potential subject to completefollow-up examinations during the study and would, in the opinion of theinvestigator, make the potential subject unsuitable for the study.